Načítá se...

EXTH-36. PHARMACEUTICAL INHIBITION OF CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) IN GLIOBLASTOMA

Potent and selective CDK4/6 inhibitors (CDK4/6i) have potential for treating glioblastoma. Although genomic abnormalities affecting CDK4/6-RB1 signaling axis, such as CDK4 or CDK6 amplification and CDKN2A deletion, which are frequent in GBM, have been proposed to predict response of RB1-wildtype GBM...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Nuga, Oluwademilade, Meng, Yuling, Berezovsky, Artem, Nelson, Kevin, de Carvalho, Ana
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651447/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.390
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!